The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

When Emily Munson started working for Indiana Disability Rights in 2015, 40 employers in the state were permitted to pay ...

Purdue announced an exciting new collaboration and earned accolades for several online programs this week. Derek Schultz has it all in the latest edition of “Purdue News Now” from Indianapolis. Plus, ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

INDIANAPOLIS (Mirror Indy ... best known for introducing mass insulin production at Eli Lilly and Co. Woollen was 32 when he was chosen for the project. Because of his youth and relative inexperience, ...